Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Claxton

Showing results (21-30 of 118) with videos related to

Pageof 12
Sort By:
Health Economics|April 3, 2018
The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortalityKarl Claxton, James Lomas, Stephen Martin
Health Policy and Planning|August 19, 2021
Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countriesJames Lomas, Karl Claxton, Jessica Ochalek
Journal of Health Services Research & Policy|November 14, 2008
Decision analysis for resource allocation in health careSusan Griffin, Karl Claxton, Mark Sculpher
BMJ (Clinical Research Ed.)|July 1, 2026
Health costs of the UK-US trade deal on pharmaceuticalsSamuel Cross, Karl Claxton, Andrew Hill
Health Economics|January 4, 2006
Evidence synthesis, parameter correlation and probabilistic sensitivity analysisA E Ades, Karl Claxton, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding DecisionsMark Sculpher, Karl Claxton, Steven D Pearson
Pharmacoeconomics|September 5, 2008
The NICE cost-effectiveness threshold: what it is and what that meansChristopher McCabe, Karl Claxton, Anthony J Culyer
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 31, 2009
Exploring the research decision space: the expected value of information for sequential research designsSusan Griffin, Nicky J Welton, Karl Claxton
BMJ (Clinical Research Ed.)|November 11, 2025
Equitable access to costly new drugsBeth Woods, Renske Ten Ham, Karl Claxton
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 24, 2018
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsJames Lomas, Karl Claxton, Stephen Martin, et al.
Pageof 12

Showing results (21-30 of 118) with videos related to

Sort By:
Pageof 12
Health Economics|April 3, 2018
The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortalityKarl Claxton, James Lomas, Stephen Martin
Health Policy and Planning|August 19, 2021
Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countriesJames Lomas, Karl Claxton, Jessica Ochalek
Journal of Health Services Research & Policy|November 14, 2008
Decision analysis for resource allocation in health careSusan Griffin, Karl Claxton, Mark Sculpher
BMJ (Clinical Research Ed.)|July 1, 2026
Health costs of the UK-US trade deal on pharmaceuticalsSamuel Cross, Karl Claxton, Andrew Hill
Health Economics|January 4, 2006
Evidence synthesis, parameter correlation and probabilistic sensitivity analysisA E Ades, Karl Claxton, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding DecisionsMark Sculpher, Karl Claxton, Steven D Pearson
Pharmacoeconomics|September 5, 2008
The NICE cost-effectiveness threshold: what it is and what that meansChristopher McCabe, Karl Claxton, Anthony J Culyer
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 31, 2009
Exploring the research decision space: the expected value of information for sequential research designsSusan Griffin, Nicky J Welton, Karl Claxton
BMJ (Clinical Research Ed.)|November 11, 2025
Equitable access to costly new drugsBeth Woods, Renske Ten Ham, Karl Claxton
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 24, 2018
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsJames Lomas, Karl Claxton, Stephen Martin, et al.
Pageof 12